Clinical Trial

A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the benefits and risks of conversion of existing adolescent kidney allograft recipients aged 12 to less than 18 years of age to a belatacept-based immunosuppressive regimen as compared to continuation of a calcineurin inhibitor-based regimen and their adherence to immunosuppressive medications.
Protocol Amendment History 28 amendments
This ClinicalTrials.gov record has been amended 28 times since 2021-05-06; most recent amendment 2026-06-22.
Status change: Not Yet Recruiting → Recruiting 2022-03-22
Trial Details
NCT Number NCT04877288
Lead Sponsor Bristol-Myers Squibb
Conditions Renal Allograft Recipients
Enrollment 102 participants
Start Date 2021-07-21
Primary Completion 2032-12-30 (estimated)
Study Completion 2034-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-25